Document is current

Article History

Received: 25 January 2021

Accepted: 2 March 2021

First Online: 18 March 2021

Funding

: This study was supported by a Sanofi investigator-initiated study grant. Sanofi reviewed the final manuscript but had no influence in the design, conduct of the trial or final analyses. The journal’s Rapid Service Fee was supported by Sanofi.

: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

: Elaine Chow has received travel and conference, honoraria for giving lectures and research support from Sanofi, Medtronic and Novartis. Juliana C.N. Chang has received research grants and/or honoraria for consultancy or giving lectures from Astra Zeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi-Sanyko, Eli-Lilly, GlaxoSmithKline, Merck Serono, Merck Sharp & Dohme, Novo Nordisk, Pfizer and Sanofi. Alice P.S. Kong has received research grants and/or speaker honoraria from Abbott, Astra Zeneca, Eli-Lilly, Merck Serono, Nestle and Novo Nordisk. The proceeds have been donated to the Chinese University of Hong Kong and other charity organizations to support diabetes research and education. James Ling, Emily W. M. Poon, Aimin Yang, Theresa Yeung, Kitman Loo, Risa Ozaki, Ronals CW and Andrea OY Luk have nothing to disclose.

: The study was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee. The study was performed in accordance with Good Clinical Practice and the Declaration of Helsinki 1964 and its later amendments. All patients provided voluntary written informed consent prior to trial participation.

: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.